Medline Inc. (MDLN) Guidance & Earnings Results
On 2026-08-05 Medline Inc. mixed guidance: "Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MDLNMedline Inc.Follow MDLN — free
—
Price chart with a free account
- Market cap
- 44.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Mixed | Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B) · full year |
| 6 May 26 | Raised | Organic Sales guidance raised to 8.5%-9.5% from 8%-9% · full year |
| 25 Feb 26 | Raised | FY2026 organic sales growth 8-9%, adjusted EBITDA $3.5-$3.6B · full year |
Medline Inc. — questions
- What guidance did Medline Inc. give?
- On 2026-08-05: "Organic sales guidance raised to 9-10% (from 8.5-9.5%); Adj EBITDA guidance cut to $3.3-3.4B (from $3.5-3.6B)"
- When does Medline Inc. report earnings?
- Medline Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Medline Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.